GlobeNewswire

Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen

Share

Global study designed to assess the efficacy and safety of suvodirsen in DMD patients amenable to exon 51 skipping

Results intended to support regulatory approvals globally

CAMBRIDGE, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of DYSTANCE 51, the Phase 2/3 efficacy and safety clinical trial of suvodirsen, an investigational stereopure oligonucleotide intended for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.

“The initiation of the DYSTANCE 51 Phase 2/3 study represents a significant milestone for Wave and our DMD clinical program, as well as an important development for the families affected by Duchenne,” said Michael Panzara, MD, MPH, Chief Medical Officer of Wave Life Sciences. “We are grateful to be working in collaboration with the U.S. Food and Drug Administration, global regulators and our partners from the Duchenne community on this innovative and exciting trial.  We are proud to have worked with patient groups to incorporate their feedback into the trial design to better address the needs of boys and families living with DMD.”

"We are pleased that Wave Life Sciences has incorporated important input from the Duchenne community in designing their Phase 2/3 clinical trial of suvodirsen. This global study is designed around the needs of families while measuring a robust set of biomarker and functional endpoints. PPMD looks forward to learning more about this stereopure exon-skipping program when Wave presents at our 25th Annual Conference later this week," said Pat Furlong, founding President and CEO of Parent Project Muscular Dystrophy (PPMD).

DYSTANCE 51 is a global study and is expected to include clinical trial sites in the United States, Europe, Australia, Canada and Japan. Results from this trial are intended to support global regulatory filings for suvodirsen.

DYSTANCE 51 Phase 2/3 Clinical Trial Design
DYSTANCE 51 is a global Phase 2/3, multicenter, randomized, double-blind, placebo-controlled clinical trial that will evaluate the efficacy and safety of suvodirsen in ambulatory boys who are between 5 and 12 years of age (inclusive) with a genetically confirmed diagnosis of DMD amenable to exon 51 skipping. The trial will test two dose levels of suvodirsen and is expected to enroll approximately 150 patients. The primary efficacy endpoints of the clinical trial will measure change in dystrophin protein level and change in the North Star Ambulatory Assessment (NSAA) score. In addition to the NSAA, the trial will include other functional outcome measures as secondary efficacy endpoints.

The DYSTANCE 51 clinical trial is the first study ever selected by the U.S. Food and Drug Administration (FDA) for its pilot program for complex innovative trial designs. As a participant in the pilot program, the company has held multiple meetings with FDA staff to discuss the design elements of the trial, including the potential use of Bayesian methods to adapt the trial with the aim of maximizing efficiency while ensuring robust clinical results.

About Suvodirsen 
Suvodirsen is an investigational stereopure oligonucleotide currently being evaluated in an ongoing open-label extension (OLE) study for the treatment of boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. Data from the company’s completed Phase 1 clinical trial of suvodirsen demonstrated a favorable safety and tolerability profile after single doses, supporting its continued clinical development, including the launch of DYSTANCE 51 and continuation of the OLE study. Wave remains on track to deliver an interim analysis of dystrophin expression from muscle biopsies in boys receiving suvodirsen in the OLE study in the second half of 2019.

Approximately 13% of DMD patients have genetic mutations that are amenable to treatment with an exon 51 skipping therapy. Exon-skipping technology has the potential to induce cellular machinery to ‘skip over’ a targeted exon and restore the reading frame, resulting in the production of internally truncated, but functional dystrophin protein.

Suvodirsen has been granted orphan drug designation for the treatment of DMD by the FDA and the European Commission, as well as rare pediatric disease designation by the FDA. Pending positive clinical dystrophin expression data, the company expects to file for an accelerated approval of suvodirsen in the United States in the second half of 2020.

About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a fatal X-linked genetic neuromuscular disorder caused predominantly by out-of-frame deletions in the dystrophin gene, resulting in absent or defective dystrophin protein. Dystrophin protein is needed for normal muscle maintenance and operation. Because of the genetic mutations in DMD, the body cannot produce functional dystrophin, which results in progressive and irreversible loss of muscle function, including the heart and lungs. Worldwide, DMD affects approximately one in 5,000 newborn boys.

About Wave Life Sciences
Wave Life Sciences (NASDAQ: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the countries in which the Phase 2/3 clinical trial for suvodirsen is expected to be conducted, the expected timing and plans to report interim data from the ongoing OLE, the belief that the safety and tolerability data from the Phase 1 clinical trial support initiation of the Phase 2/3 clinical trial, the anticipated benefits of participating in FDA’s complex innovative trial designs pilot program, the intention to use the results of the OLE and Phase 2/3 trials to seek various regulatory approvals globally and the anticipated timing of such regulatory filing in the U.S. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. These risks and uncertainties include but are not limited to the following: Wave’s current and planned clinical trials, other studies for suvodirsen and Wave’s other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in later-stage or larger-scale clinical trials; and the other risk factors discussed under the heading “Risk Factors” contained in Wave’s Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission (SEC), as well as in other filings Wave makes with the SEC from time to time. All statements contained in this press release are made only as of the date of this press release, and Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media and Patient Contact:
José Juves
617-949-4708
jjuves@wavelifesci.com

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Heijmans and De Wever: 220 homes in Berkel-Enschot and Tilburg12.11.2019 17:30:00 CETPress release

Heijmans and geriatric care organization De Wever, which is an organisation that provides care to the elderly, have concluded a cooperation agreement for the phased development of approximately 220 owner-occupier and rental homes in Berkel-Enschot and Tilburg. Part of the homes (112 care apartments) is intended for senior citizens with divergent care needs. The project is valued at around € 65 million. Heijmans and De Wever respond to the increasing demand for suitable homes for senior citizens in Berkel-Enschot and Tilburg by means of this cooperation. Part of the apartments is intended for senior citizens who require nursing home care. With this project Heijmans contributes to creating a healthy living environment for these target groups. The project focuses among other things on laying out indoor and outdoor spaces intended for shared use, as a result of which residents can meet each other. A new apartment complex with 52 apartments for hospital (intramural) care is being realized i

Prosafe SE: Mandatory notification of trade12.11.2019 16:09:00 CETPress release

Ryan Stewart, Chief Commercial Officer, has on 12 November 2019 purchased 45,000 shares in Prosafe SE at an average price of NOK 4.2565 per share. Following the transaction, Ryan Stewart owns 45,260 shares in Prosafe SE. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The Company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger, 12 November 2019 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig H. Christiansen, Deputy CEO and CFO Phone: +47 51 64 25 17 / +47 478 07 813 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

SDLP - Seadrill Partners LLC Third Quarter 2019 Cash Distribution12.11.2019 15:37:00 CETPress release

London, United Kingdom, November 12, 2019 - Seadrill Partners LLC (OTCQB:SDLPF) ("Seadrill Partners" or the "Company") announces today that a distribution of $0.01 per unit has been declared with respect to the third quarter ended September 30, 2019, in line with the second quarter distribution. The third quarter cash distribution will be paid on November 27, 2019 to all unitholders of record as of the close of business on November 22, 2019. FORWARD LOOKING STATEMENTS This news release includes forward looking statements. Such statements are generally not historical in nature, and specifically include statements about the Company's plans, strategies, business prospects, changes and trends in its business and the markets in which it operates. In particular, statements regarding offshore drilling markets, the Company's ability to make cash distributions, the expected performance of the drilling units in the Company's fleet, estimated duration of customer contracts, contract dayrate amoun

DNO ASA: FAPE01 bond buyback12.11.2019 15:25:00 CETPress release

Oslo, 12 November 2019 - DNO ASA, the Norwegian oil and gas operator, today purchased USD 2.6 million in nominal value of FAPE01 bonds (ISIN NO0010811268) originally issued by Faroe Petroleum plc, and renamed DNO North Sea plc. The bonds were purchased at a price of 107.25. Following the bond buyback, USD 23.6 million in nominal value of the FAPE01 bonds remain outstanding with DNO ASA holding the balance of USD 62.2 million. The FAPE01 bonds mature on 28 April 2023. -- For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands, Ireland and Yemen. This information is subject to the disclosure requirements pursuant

PCI Biotech to present at BIO-Europe 201912.11.2019 15:11:00 CETPress release

Oslo, Norway, November 12, 2019 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present at BIO-Europe 2019 being held November 11-13, 2019 at Hamburg Messe, Germany. On Wednesday, November 13, 2019 at 09:15am (CET), Dr. Per Walday, CEO, will present an overview of PCI Biotech’s technology and the multiple business development and commercial opportunities available based on this proprietary platform. The presentation will be made available on PCI Biotech’s website (www.pcibiotech.com ) under “Other presentations”. About PCI Biotech PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fi